Application(s): positive control for WB · Source: mouse recombinant hexahistidine-tagged protein expressed in E. coli · M_r: 18 kDa (His-tagged), 15 kDa (native) · Fatty acid binding protein 4 (FABP4) is one of nine known cytosolic FABPs ranging in size from 14-15 kDa containing 127-132 amino acids.¹ Members of this protein family exhibit high affinity for small lipophilic ligands and were named according to the tissue from which they were initially isolated.¹ Studies suggest that FABPs are involved in the uptake and metabolism of fatty acids, in the maintenance of cellular membrane fatty acid levels, in intracellular trafficking of these substrates, in the modulation of specific enzymes of lipid metabolic pathways, and in the modulation of cell growth and differentiation.² Studies using FABP4 gene deletion in mice indicate a dominant role for FABP4 in several chronic metabolic diseases. Therefore, inhibiting the function of FABP4 is a potential mechanism for the treatment of metabolic diseases like diabetes and atherosclerosis.^3,4

1 Zimmerman, A.W., and Veerkamp, J.H. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 59 1096-1116 (2002).

2 Massolini, G., and Calleri, E. Survey of binding properties of fatty acid-binding proteins chromatographic methods. J Chromatogr B 797 255-268 (2003).

3 Furuhashi, M., Tuncman, G., Görgün, C.Z., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447 959-965 (2007).

4 Boord, J.B., Maeda, K., Makowski, L., et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 22 1686-1691 (2002).

Zimmerman, A.W., and Veerkamp, J.H. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 59 1096-1116 (2002).

Boord, J.B., Maeda, K., Makowski, L., et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 22 1686-1691 (2002).

Furuhashi, M., Tuncman, G., Görgün, C.Z., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447 959-965 (2007).

Massolini, G., and Calleri, E. Survey of binding properties of fatty acid-binding proteins chromatographic methods. J Chromatogr B 797 255-268 (2003).

Show all 4 Hide all but first 3